Loading organizations...
§ Venture Capital · Qingdao, Fujian, China
venture capital firm investing in and supporting technology startups, providing early-stage funding for emerging companies.
Jing Capital operates as a professional private equity investment management institution, strategically deploying capital into China's burgeoning new economy and emerging industries. The firm concentrates its investments across vital sectors such as life sciences, enterprise upgrading initiatives, advanced hard technology, and new energy solutions. Its distinctive investment approach integrates both Funds of Funds (FOFs) and direct investment strategies, positioning it at the vanguard of the dynamic investment landscape.
The institution was founded by Chen Dawei, who serves as the Founding Managing Partner, and Li Shihua, a Managing Partner. Their collaborative vision underpins Jing Capital’s operational philosophy, which is fundamentally rooted in the concept of "Investing in Entrepreneurs." This principle guides their strategic decisions and reflects a commitment to nurturing innovative ventures and impactful leaders within their target markets.
Jing Capital targets companies and projects that are shaping the future of China's economy, providing essential capital and strategic guidance. The firm's long-term vision is centered on identifying and empowering the next generation of industry leaders, thereby driving innovation and contributing significantly to the development of the new economy sectors it supports. It aims to remain at the forefront by consistently backing entrepreneurial endeavors.
Chuangjing Capital has 1 tracked investment across 1 company. The latest tracked deal is $42.1M Series B in iRegene Therapeutics in September 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Sep 9, 2025 | iRegene Therapeutics | $42.1M Series B | Chuangjing Capital, Northern Light Venture Capital, Onehealth Haihe Capital | — |